Extrapyramidal symptoms — EPS — are the family of movement disorders that D2 blockade in the nigrostriatal pathway produces. The mechanism is dopamine-acetylcholine imbalance in the striatum: when D2 is blocked, the cholinergic system loses its dopaminergic counterweight and produces movement abnormalities. Four subtypes are distinguished by time course, presentation, and treatment.
- Class
- Pharmacology of D2-blockade movement effects
- Mechanism
- Nigrostriatal D2 blockade disrupts striatal dopamine-acetylcholine balance → movement disorders. Different EPS subtypes reflect different timecourses and possibly mechanisms.
- FDA indications
- Recognition and treatment framework for the spectrum
- Key adverse effects
- Acute dystonia (hours-days), akathisia (anytime), parkinsonism (days-weeks), tardive dyskinesia (months-years)
Acute dystonia: anticholinergic (benztropine, diphenhydramine). Akathisia: beta-blocker (propranolol), benzodiazepine, switch to lower-EPS agent. Parkinsonism: anticholinergic, dose reduction, switch. Tardive dyskinesia: VMAT2 inhibitor (valbenazine, deutetrabenazine), avoid further FGA exposure.
Acute dystonia emerges hours to days after antipsychotic initiation or dose increase. Sustained, painful muscle contractions: torticollis (neck), tongue protrusion or oculogyric crisis (eyes rolled up), or — life-threatening — laryngeal dystonia compromising the airway. Highest incidence in young men receiving high-potency FGAs. Treatment: IM or IV benztropine 1-2 mg or diphenhydramine 25-50 mg. Reversal is dramatic and rapid. Counsel the patient and provide oral prophylaxis with subsequent doses.
Akathisia can emerge at any time but often within days to weeks. Subjective inner restlessness paired with motor restlessness — pacing, inability to sit still, sometimes leg-jiggling. It is frequently misdiagnosed as anxiety or agitation, and severely distressing — associated with treatment discontinuation and increased suicide risk. Treatment: propranolol 20-80 mg per day is first-line, benzodiazepines (lorazepam, clonazepam) short-term, dose reduction, or switch. Anticholinergics like benztropine — effective for dystonia and parkinsonism — are NOT effective for akathisia.
Parkinsonism emerges over days to weeks. Tremor, rigidity, bradykinesia, masked facies — the classic Parkinson's phenotype, produced pharmacologically. Treatment: dose reduce, add anticholinergic (benztropine), or switch to lower-EPS-risk agent.
Extrapyramidal symptoms are not a side effect to memorize but a direct consequence of D2 blockade in the nigrostriatal pathway — each EPS subtype maps to a mechanism and a treatment.
Mechanism note: EPS is the nigrostriatal cost of D2 blockade. Each subtype has a distinct timeline, mechanism, and treatment — the clinical skill is matching the presentation to the right intervention.
Tardive dyskinesia emerges over months to years. Choreoathetoid movements — often oral-facial (lip-smacking, tongue protrusion, chewing) plus limb involvement. Often irreversible. Treatment: VMAT2 inhibitors (valbenazine, deutetrabenazine) are the first effective pharmacologic treatment. Minimize antipsychotic exposure. Counterintuitively, anticholinergics worsen TD — discontinue them. Prevention is the strategy: AIMS exam annually on all antipsychotics; minimize FGA exposure when SGA serves equally; consider clozapine for high-risk patients.
Each EPS subtype has its own time course, presentation, and treatment. Recognizing which you're looking at determines what you do.